文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

68Ga-PSMA-PET描绘前列腺切除术后放疗失败部位

Delineating sites of failure following post-prostatectomy radiation treatment using 68Ga-PSMA-PET.
PubMed 文献 · Radiother Oncol · 2017-11-10

该研究纳入409例前列腺切除术后接受IMRT的患者,其中310例仅照射前列腺窝(PF),99例照射PF+盆腔淋巴引流区(PF+LN)。119例出现生化失败(BF),81例按研究计划行PSMA-PET显像,67例(80%)发现PSMA avid病灶。PF组野内失败仅2/50(4%),PF+LN组1/17(6%);单纯淋巴结失败在PF组为33/50(66%),PF+LN组为7/17(41%)。

要点

  • 前列腺切除术后放疗野内控制率优秀,PF组和PF+LN组野内失败分别仅4%和6%。
  • PF组单纯淋巴结失败占66%,其中55%为盆腔-only淋巴结失败,显著高于PF+LN组的14%(p=0.03)。
  • PF组PSMA avid失败中32%会被标准盆腔淋巴放疗体积覆盖。

核心结论

  • 前列腺切除术后放疗野内控制率优秀。
  • 接受PF+LN放疗者孤立盆腔淋巴结失败罕见,而仅接受PF放疗者中盆腔淋巴结失败占失败的三分之一。

研究设计与样本

  • 2006年6月至2016年1月间,409例前列腺切除术后患者接受调强放疗(IMRT),310例仅照射前列腺窝(PF),99例照射PF+盆腔淋巴引流区(PF+LN),后者常联合雄激素剥夺(AD)治疗。
  • 对常规影像未发现的失败病灶行68Ga-PSMA-PET(PSMA-PET)显像描绘。

主要发现

  • 119例出现生化失败(BF,定义为PSA较放疗后最低值升高>0.2或更高)。
  • PF组无BF生存率为71%,PF+LN组为70%,中位随访分别为52个月和44个月。
  • PF组和PF+LN组分别有13%和92%的患者同时使用AD。
  • 81例BF患者(68%)按研究意图行PSMA-PET显像,其中67例(80%)发现PSMA avid病灶。
  • PSMA-PET描绘的野内失败在PF组为2/50(4%),PF+LN组为1/17(6%);单纯淋巴结失败在PF组为33/50(66%),PF+LN组为7/17(41%);PF组单纯淋巴结失败者中18/33(55%)为盆腔-only淋巴结失败,PF+LN组为1/7(14%)(p=0.03)。

关键数值与推荐

  • 生化失败定义为PSA较放疗后最低值升高>0.2或更高。
  • 失败部位分为野内(PF±LN)或野外(单纯淋巴结、单纯远处转移(内脏或骨)或多部位失败)。
  • PF组PSMA avid失败中16例(32%)会被标准盆腔淋巴放疗体积覆盖。

临床怎么用

  • 前列腺切除术后放疗后生化失败患者可行PSMA-PET显像以区分野内与野外失败。
  • 仅照射前列腺窝者需关注盆腔淋巴结失败风险,PF+LN放疗可降低孤立盆腔淋巴结失败。
  • 标准盆腔淋巴放疗体积可覆盖部分PSMA avid失败病灶。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To identify sites of failure with 68Ga-PSMA-PET (PSMA-PET) imaging in patients who have Biochemical Failure (BF) following post-prostatectomy radiotherapy. MATERIAL AND METHODS: Between June 2006 and January 2016, 409 men received post prostatectomy intensity modulated radiation treatment (IMRT) with protocolised planning. 310 patients received radiation treatment (RT) to the Prostate Fossa (PF) alone and 99 patients received RT to PF and pelvic lymphatics (PF + LN) usually in combination with androgen deprivation (AD) therapy. Any failure not detected on conventional imaging was delineated with PSMA-PET scanning. Sites of failure were characterised as in-field (PF ± LN), or out of field (nodal alone, distant metastatic alone (visceral or bone) or multi-site failure). Nodal failure was further divided into pelvic failure and/or distant failure. RESULTS: 119 men developed BF, defined as a PSA rise of >0.2 or greater, above post-RT nadir. Freedom from BF was 71% in the PF group and 70% in the PF + LN group, with median follow up of 52 and 44 months respectively. AD was used concomitantly in 13% of the PF group and 92% of the PF + LN group. 81 patients with BF (68%) had PSMA-PET imaging performed as per study intent, 67 (80%) of whom had PSMA avid disease identified. PSMA-PET delineated in-field failure occurred in 2/50 (4%) of the PF group and 1/17 (6%) in the PF + LN group. Nodal failure alone was 33/50 (66%) for the PF group vs 7/17 (41%) for the PF + LN group. For the nodal only failure patients, 18/33 (55%) had pelvic-only nodal failure in the PF group compared to 1/7 (14%) in the PF + LN group (p = 0.03). 16 (32%) of the PSMA avid failures in the PF group would have been encompassed by standard pelvic lymphatic radiotherapy volumes. CONCLUSION: Post-prostatectomy radiation treatment resulted in excellent in-field control rates. Isolated pelvic nodal failure was rare in those receiving radiotherapy to the prostatic fossa and pelvic nodes but accounted for one third of failures in those receiving PF alone treatment.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Byrne K, Eade T, Kneebone A, et al. Delineating sites of failure following post-prostatectomy radiation treatment using 68Ga-PSMA-PET. Radiother Oncol. 2017. PMID: 29132644. doi:10.1016/j.radonc.2017.10.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。